Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03218761 · ClinicalTrials.gov registry record

POTS NET mRNA Functional Correlation With NET Activity

A clinical trial of Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.

Active
Registry status
200
Enrollment target
1
Study location

NCT03218761: Active study of Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.

NCT03218761 is a study of Postural Tachycardia Syndrome that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 200 participants, above the 72-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (178% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03218761, a study of Postural Tachycardia Syndrome, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

Primary Outcome

NET mRNA above and below median supine plasma DHPG:NE

Interventions

  • DIAGNOSTIC_TEST NET mRNA level
  • DIAGNOSTIC_TEST Plasma catechols
  • DIAGNOSTIC_TEST Urine Catechols

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-07-14
Est. Completion 2029-12-31

What the registry record for NCT03218761 still lists

NCT03218761 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 72-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (178% higher).

The record links to 1 condition, with Postural Tachycardia Syndrome appearing as the primary indexed condition, and to 3 interventions - of which NET mRNA level is the first listed.

NCT03218761 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT03218761 about?

NCT03218761 is a clinical study titled "POTS NET mRNA Functional Correlation With NET Activity". DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome...

What is the current status of trial NCT03218761?

This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2017-07-14. Estimated completion is 2029-12-31.

What conditions does trial NCT03218761 study?

This clinical trial studies the following conditions: Postural Tachycardia Syndrome.

What interventions are being tested in trial NCT03218761?

The interventions under investigation include: NET mRNA level (DIAGNOSTIC_TEST), Plasma catechols (DIAGNOSTIC_TEST), Urine Catechols (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03218761?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03218761 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postural Tachycardia Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03218761's enrollment target sits among peer trials

200 2nd of 19 the highest of 19 other Postural Tachycardia Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Postural Tachycardia Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03218761, the US trial registry maintained by the National Library of Medicine. NCT03218761 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.